Is SLN a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Silence Therapeutics (SLN) rests on Divesiran after a positive SANRECO Phase 2: The SANRECO readout arrived in August 2026 and met its primary endpoint: an 88% responder rate on divesiran versus 19% on placebo (p<0.0001), with 93.8% responding on every-6-week dosing and 81.3% on every-12-week dosing among 48 phlebotomy-dependent patients. The bear case rests on silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. Analysts covering it publish targets from $19.00 to $20.00 against a $19.80 share price on November 16, 2026, so even the professionals disagree by 5% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
SLN key stats
At $19.80 on November 16, 2026, Silence Therapeutics (SLN) has a market cap of $1.2B.
- Market cap
- $1.2B
- Price to book
- 24.3
- Beta
- 1.34
Market cap, P/E and yield are measured at the $19.80 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Silence Therapeutics (SLN)?
The last two weeks for Silence Therapeutics, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- SLN closed at $19.80 on November 16, 2026, up 0.3% over the past five trading days (from $19.75).
- On November 13, 2026, Silence Therapeutics filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 12, 2026, Silence Therapeutics filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Silence Therapeutics plc is a London-headquartered biotechnology company built around short interfering RNA, a class of drug that switches off the production of a specific disease-causing protein in the liver rather than blocking it after the fact. Its proprietary discovery platform, marketed as mRNAi GOLD, attaches a GalNAc sugar to the siRNA so the molecule is taken up by liver cells, which is the same delivery approach behind the approved RNAi drugs on the market today. Two candidates carry the story. Zerlasiran silences the LPA gene to lower lipoprotein(a), an inherited cardiovascular risk factor with no approved therapy, and produced reductions of more than 80 percent in its Phase 2 ALPACAR-360 trial. Divesiran targets TMPRSS6 to raise hepcidin and control red blood cell production in polycythemia vera, a chronic blood cancer whose patients are otherwise managed with repeated therapeutic phlebotomy. A third asset, SLN312, was returned to Silence in March 2026 after AstraZeneca elected not to advance it past Phase 1. The investment picture is still binary, but the first big binary has now landed. On August 10, 2026 Silence reported that divesiran met the primary endpoint of the Phase 2 SANRECO trial: 88% of patients were responders (no phlebotomy and hematocrit below 45% during weeks 18-36) against 19% on placebo, and divesiran patients averaged 0.2 phlebotomies over 36 weeks versus 2.1 on placebo, with no new safety findings. A Phase 3 trial of every-12-week dosing against placebo is expected to start in the first half of 2027. The company used the moment to sell about 14.9 million ADSs at $13.50 each, including the underwriters' full option, for gross proceeds of about $201 million, adding substantially to the roughly $72 million of cash and short-term investments it held at June 30, 2026. Collaboration revenue remains negligible (about $0.6 million on a trailing basis, down from roughly $34 million in 2024), and management still says it will start zerlasiran's Phase 3 cardiovascular outcomes trial only once a partner is secured. The stock has given back much of its post-data jump: it closed near $8.81 on October 16, 2026, below the $13.50 offering price and down about 28% in the past month, though still up about 43% year to date and 34% over one year.
The bull case: what would have to be true for $20.00
The most optimistic published target on SLN is $20.00, +1.0% from the $19.80 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Divesiran after a positive SANRECO Phase 2
The SANRECO readout arrived in August 2026 and met its primary endpoint: an 88% responder rate on divesiran versus 19% on placebo (p<0.0001), with 93.8% responding on every-6-week dosing and 81.3% on every-12-week dosing among 48 phlebotomy-dependent patients. Divesiran patients needed an average of 0.2 phlebotomies over 36 weeks against 2.1 on placebo. Silence owns the program outright and plans a Phase 3 of every-12-week dosing versus placebo starting in the first half of 2027. The open questions now are Phase 3 design, cost, and timing, and how the data compares with Protagonist and Takeda's rusfertide once full results are presented at a medical congress.
2. A partner for zerlasiran
Zerlasiran is described as Phase 3 ready for lipoprotein(a) driven cardiovascular disease, with the core readiness work finished, but Silence has committed to starting the outcomes trial only after securing a third party to fund it. A cardiovascular outcomes trial in this setting runs for years and costs far more than the company's current cash balance, so the deal itself, not the science, is the gating item. Terms of any such agreement, including upfront cash and retained economics, would set how much of the asset shareholders still own.
3. A larger cash pile after the August raise
Quarterly research spend was cut by more than half year over year in early 2026, and net losses ran about $11 million in the first quarter and about $9 million in the second. Before the offering, about $72 million of cash and short-term investments at June 30, 2026 was guided to fund operations into 2028. The August 2026 upsized offering then brought in about $201 million gross at $13.50 per ADS, which gives Silence the capacity to fund a divesiran Phase 3 itself, at the cost of roughly 15 million new ADSs, about a third more than the roughly 47 million outstanding earlier in the year.
4. Platform optionality beyond the lead assets
The mRNAi GOLD platform has generated liver-directed candidates across cardiovascular, hematology and metabolic targets, including early work on siRNA approaches to obesity. SLN312 came back in-house in March 2026 when AstraZeneca declined to continue past Phase 1, giving Silence full global rights to evaluate on its own terms. Platform breadth matters mainly as a source of future partnering revenue, since the company has neither the capital nor the intent to develop everything alone.
The bear case: what would have to be true for $19.00
The most pessimistic published target is $19.00, -4.0% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Silence Therapeutics is worth if the risks below bite instead of the drivers above.
Silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. The SANRECO Phase 2 succeeded, but Phase 2 results in 48 patients do not guarantee a Phase 3 win, and the planned Phase 3 will take years and consume a large part of the cash raised in August 2026. A partner for zerlasiran may not appear on acceptable economics or at all, which would leave the larger asset stranded. Dilution is no longer hypothetical: the August offering added about 14.9 million ADSs at $13.50, and the stock has since traded well below that price, closing near $8.81 on October 16, 2026 after a 28% fall in a month. Competition is well funded on both fronts: several large pharmaceutical companies are running Phase 3 lipoprotein(a) programs, and polycythemia vera already has approved and late-stage alternatives, including rusfertide aimed at the same hepcidin biology. Because the ADSs represent three ordinary shares each, per-share figures quoted for the Nasdaq listing and the underlying UK share count are not directly comparable, which is a frequent source of confusion when reading coverage.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding SLN already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on SLN
4 analysts cover SLN, with an average target of $19.75 (-0.3% against $19.80) and a split of 1 buy, 4 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the SLN forecast and price target page.
How is SLN valued?
Market cap, P/E and dividend yield at today's price are in the SLN key stats above. The business figures below come from Silence Therapeutics's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$0.6M (collaboration revenue only, down from ~$34M in FY2024)
- Net loss (TTM): ~$60M; Q2 2026 net loss ~$9M
- Cash and short-term investments (June 30, 2026): ~$72M, before ~$201M gross raised in August 2026
- August 2026 offering: ~14.9M ADSs at $13.50, including full underwriter option
As of October 2026: Conventional valuation multiples do not apply: trailing revenue is under $1 million, so price-to-sales (about 890x) and price-to-earnings are arithmetic noise. Adding the roughly $201 million of gross offering proceeds to the $72 million held at June 30 suggests cash in the region of $250 million or more after fees and third-quarter spending, so a roughly $548 million market cap implies the market values divesiran, zerlasiran and the platform at about $300 million. Figures are approximate and as of October 16, 2026; the third-quarter report, expected around November 5 (an estimated date), will show the actual post-raise cash balance.
How do you decide if SLN is a buy?
Whether SLN is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold SLN indirectly through an index or sector ETF before adding more.
What would change your mind on SLN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Divesiran after a positive SANRECO Phase 2 stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the SLN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SLN against your real portfolio and see your actual exposure before deciding.
Your questions about Silence Therapeutics
Ask Walnut's AI anything about SLN and see how it fits what you own.
FAQ
Is SLN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Divesiran after a positive SANRECO Phase 2, with revenue (ttm) at ~$0.6M (collaboration revenue only, down from ~$34M in FY2024). The bear case rests on silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. Analysts covering it are spread from $19.00 to $20.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell SLN?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $19.00, -4.0% from the $19.80 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for SLN?
+
Divesiran after a positive SANRECO Phase 2. The SANRECO readout arrived in August 2026 and met its primary endpoint: an 88% responder rate on divesiran versus 19% on placebo (p<0.0001), with 93.8% responding on every-6-week dosing and 81.3% on every-12-week dosing among 48 phlebotomy-dependent patients. The most optimistic analyst target on SLN is $20.00, +1.0% from the $19.80 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for SLN?
+
Silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. The SANRECO Phase 2 succeeded, but Phase 2 results in 48 patients do not guarantee a Phase 3 win, and the planned Phase 3 will take years and consume a large part of the cash raised in August 2026. A partner for zerlasiran may not appear on acceptable economics or at all, which would leave the larger asset stranded. Dilution is no longer hypothetical: the August offering added about 14.9 million ADSs at $13.50, and the stock has since traded well below that price, closing near $8.81 on October 16, 2026 after a 28% fall in a month. Competition is well funded on both fronts: several large pharmaceutical companies are running Phase 3 lipoprotein(a) programs, and polycythemia vera already has approved and late-stage alternatives, including rusfertide aimed at the same hepcidin biology. Because the ADSs represent three ordinary shares each, per-share figures quoted for the Nasdaq listing and the underlying UK share count are not directly comparable, which is a frequent source of confusion when reading coverage. The most pessimistic published target is $19.00, -4.0% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Silence Therapeutics do?
+
Silence Therapeutics is a UK clinical-stage biotech whose Nasdaq-listed ADSs back two siRNA programs: zerlasiran for lipoprotein(a) and divesiran for polycythemia vera.
What would have to change for SLN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Divesiran after a positive SANRECO Phase 2) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Silence Therapeutics actually do?
+
It designs short interfering RNA drugs that shut off production of a specific protein in liver cells before that protein is ever made. Its mRNAi GOLD platform attaches a GalNAc sugar to the siRNA so the liver absorbs it after a simple injection. The two lead candidates are zerlasiran for high lipoprotein(a) and divesiran for polycythemia vera.
Is SLN an ADS, and what is the ratio?
+
Yes. Silence Therapeutics plc is a UK company, and what trades on Nasdaq under SLN is an American Depositary Share representing 3 ordinary shares. Roughly 141.7 million ordinary shares were outstanding as of April 30, 2026, which corresponds to about 47 million ADSs. Any per-share figure sourced from the UK filings needs to be multiplied by three before it can be compared with the Nasdaq quote. The August 2026 offering added about 14.9 million ADSs, so the ADS-equivalent count is now meaningfully higher than the April figure.
Does Silence Therapeutics have any revenue?
+
Almost none. Trailing twelve-month revenue is roughly $0.6 million, all of it collaboration revenue recognized from the AstraZeneca agreement, down from about $34 million in fiscal 2024 when partnership milestones were flowing. The second quarter of 2026 recorded no revenue at all. The company has no approved product and no product sales, so the drop reflects the timing of partnership accounting rather than a business that shrank.
Walnut is informational, not investment advice, and gives no verdict on SLN. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.